全文获取类型
收费全文 | 16703篇 |
免费 | 3641篇 |
国内免费 | 54篇 |
学科分类
医药卫生 | 20398篇 |
出版年
2023年 | 815篇 |
2022年 | 158篇 |
2021年 | 732篇 |
2020年 | 673篇 |
2019年 | 535篇 |
2018年 | 1031篇 |
2017年 | 1014篇 |
2016年 | 948篇 |
2015年 | 861篇 |
2014年 | 1146篇 |
2013年 | 1182篇 |
2012年 | 931篇 |
2011年 | 960篇 |
2010年 | 826篇 |
2009年 | 928篇 |
2008年 | 720篇 |
2007年 | 567篇 |
2006年 | 617篇 |
2005年 | 518篇 |
2004年 | 422篇 |
2003年 | 406篇 |
2002年 | 395篇 |
2001年 | 330篇 |
2000年 | 285篇 |
1999年 | 253篇 |
1998年 | 193篇 |
1997年 | 149篇 |
1996年 | 133篇 |
1995年 | 116篇 |
1994年 | 102篇 |
1993年 | 81篇 |
1992年 | 219篇 |
1991年 | 170篇 |
1990年 | 161篇 |
1989年 | 141篇 |
1988年 | 141篇 |
1987年 | 132篇 |
1986年 | 124篇 |
1985年 | 126篇 |
1984年 | 92篇 |
1983年 | 98篇 |
1982年 | 78篇 |
1981年 | 72篇 |
1979年 | 95篇 |
1978年 | 66篇 |
1977年 | 51篇 |
1976年 | 57篇 |
1972年 | 61篇 |
1971年 | 59篇 |
1970年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 687 毫秒
1.
2.
3.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
4.
Samir Gupta MD MDCS AGAF Balambal Bharti MBBS MPH PhD Dennis J. Ahnen MD Daniel D. Buchanan PhD Iona C. Cheng PhD MPH Michelle Cotterchio PhD Jane C. Figueiredo PhD Steven J. Gallinger MD MSc Robert W. Haile DrPH MPH Mark A. Jenkins PhD Noralane M. Lindor MD Finlay A. Macrae MD AGAF Loïc Le Marchand MD PhD Polly A. Newcomb PhD MPH Stephen N. Thibodeau PhD Aung Ko Win MBBS MPH PhD Maria Elena Martinez PhD 《Cancer》2020,126(13):3013-3020
5.
Kenny P. Pang FRCSEd FRCSI Claudio Vicini MD Filippo Montevecchi MD Ottavio Piccin MD MSc Sudipta Chandra MBBS MS Hyung C. Yang MD PhD Vikas Agrawal MS DLO Joseph C. K. Chung FRCS Yiong H. Chan BSc PhD Scott B. Pang Kathleen A. Pang Edward B. Pang Brian Rotenberg MD MPH FRCSC 《The Laryngoscope》2020,130(9):2281-2284
6.
7.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献8.
9.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 下载免费PDF全文